Form 4: Voyager Therapeutics Director Jude Onyia Acquires 24,000 Stock Options

Director Jude Onyia acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• Jude Onyia, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options have an exercise price of $8.70.
• The options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The options vest upon the earlier of one year from the grant date or the date of the next annual meeting of stockholders, contingent upon continued service as a director.
• The options expire on June 5, 2034.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction (stock option grant) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology industry, to align their interests with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the biotech industry.
• The vesting schedule of one year or the next annual meeting is also typical.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also utilize stock options as part of their director compensation packages.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates